Proteo, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Proteo, Inc. - Product Pipeline Review - 2012” provides data on the Proteo, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Proteo, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Proteo, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Proteo, Inc. - Product Pipeline Review - 2012” provides data on the Proteo, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Proteo, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Proteo, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Proteo, Inc. - Brief Proteo, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Proteo, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Proteo, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Proteo, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Proteo, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Proteo, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Proteo, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Proteo, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Proteo, Inc. and identify potential opportunities in those areas.
Proteo, Inc. Snapshot
Proteo, Inc. Overview
Key Information
Key Facts
Proteo, Inc. – Research and Development Overview
Key Therapeutic Areas
Proteo, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Proteo, Inc. – Pipeline Products Glance
Proteo, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Proteo, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Proteo, Inc. – Drug Profiles
Elafin
Product Description
Mechanism of Action
R&D Progress
Leech-Derived Protein Inhibitor
Product Description
Mechanism of Action
R&D Progress
LILA
Product Description
Mechanism of Action
R&D Progress
Proteo, Inc. – Pipeline Analysis
Proteo, Inc. – Pipeline Products by Therapeutic Class
Proteo, Inc. – Pipeline Products by Route of Administration
Proteo, Inc. – Pipeline Products By Mechanism of Action
Proteo, Inc. – Recent Pipeline Updates
Proteo, Inc. - Dormant Projects
Proteo, Inc. – Company Statement
Proteo, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Proteo, Inc., Recent Developments
Proteo, Inc.- Press Release
Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants
Jun 22, 2012: Proteo Provides Update On Phase II Study Of Elafin In Coronary Bypass Surgery
Nov 16, 2009: Proteo, Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status For Elafin In The Treatment Of Esophagus Carcinoma
Sep 23, 2009: Proteo, Inc./Proteo Biotech AG Announces Phase II Clinical Trial Of Elafin For Cardiovascular Disease
Financial Deals Landscape
Proteo, Inc., Deals Summary
Proteo, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Proteo Biotech Enters Into An Agreement With USAMRIID
Proteo Biotech Enters Into Co-Marketing Agreement With ARTES Biotech
Licensing Agreements
Proteo Enters Into Licensing Agreement With Rhein Minapharm
Equity Offering
Proteo Completes Private Placement Of $3.6 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Proteo, Inc., Key Information
Proteo, Inc., Key Facts
Proteo, Inc. – Pipeline by Indication, 2012
Proteo, Inc. – Pipeline by Stage of Development, 2012
Proteo, Inc. – Monotherapy Products in Pipeline, 2012
Proteo, Inc. – Phase II, 2012
Proteo, Inc. – Pre-Clinical, 2012
Proteo, Inc. – Pipeline By Therapeutic Class, 2012
Proteo, Inc. – Pipeline By Route of Administration, 2012
Proteo, Inc. – Pipeline Products By Mechanism of Action, 2012
Proteo, Inc. – Recent Pipeline Updates, 2012
Proteo, Inc. - Dormant Developmental Projects,2012
Proteo, Inc., Subsidiaries
Proteo, Inc., Deals Summary
Proteo Biotech Enters Into An Agreement With USAMRIID
Proteo Biotech Enters Into Co-Marketing Agreement With ARTES Biotech
Proteo Enters Into Licensing Agreement With Rhein Minapharm
Proteo Completes Private Placement Of $3.6 Million
LIST OF FIGURES
Proteo, Inc. – Pipeline by Indication, 2012
Proteo, Inc. – Pipeline by Stage of Development, 2012
Proteo, Inc. – Monotherapy Products in Pipeline, 2012
Proteo, Inc. – Pipeline By Route of Administration, 2012
Proteo, Inc. - Pipeline Products By Mechanism of Action, 2012
Proteo, Inc. Overview
Key Information
Key Facts
Proteo, Inc. – Research and Development Overview
Key Therapeutic Areas
Proteo, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Proteo, Inc. – Pipeline Products Glance
Proteo, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Proteo, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Proteo, Inc. – Drug Profiles
Elafin
Product Description
Mechanism of Action
R&D Progress
Leech-Derived Protein Inhibitor
Product Description
Mechanism of Action
R&D Progress
LILA
Product Description
Mechanism of Action
R&D Progress
Proteo, Inc. – Pipeline Analysis
Proteo, Inc. – Pipeline Products by Therapeutic Class
Proteo, Inc. – Pipeline Products by Route of Administration
Proteo, Inc. – Pipeline Products By Mechanism of Action
Proteo, Inc. – Recent Pipeline Updates
Proteo, Inc. - Dormant Projects
Proteo, Inc. – Company Statement
Proteo, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Proteo, Inc., Recent Developments
Proteo, Inc.- Press Release
Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants
Jun 22, 2012: Proteo Provides Update On Phase II Study Of Elafin In Coronary Bypass Surgery
Nov 16, 2009: Proteo, Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status For Elafin In The Treatment Of Esophagus Carcinoma
Sep 23, 2009: Proteo, Inc./Proteo Biotech AG Announces Phase II Clinical Trial Of Elafin For Cardiovascular Disease
Financial Deals Landscape
Proteo, Inc., Deals Summary
Proteo, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Proteo Biotech Enters Into An Agreement With USAMRIID
Proteo Biotech Enters Into Co-Marketing Agreement With ARTES Biotech
Licensing Agreements
Proteo Enters Into Licensing Agreement With Rhein Minapharm
Equity Offering
Proteo Completes Private Placement Of $3.6 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Proteo, Inc., Key Information
Proteo, Inc., Key Facts
Proteo, Inc. – Pipeline by Indication, 2012
Proteo, Inc. – Pipeline by Stage of Development, 2012
Proteo, Inc. – Monotherapy Products in Pipeline, 2012
Proteo, Inc. – Phase II, 2012
Proteo, Inc. – Pre-Clinical, 2012
Proteo, Inc. – Pipeline By Therapeutic Class, 2012
Proteo, Inc. – Pipeline By Route of Administration, 2012
Proteo, Inc. – Pipeline Products By Mechanism of Action, 2012
Proteo, Inc. – Recent Pipeline Updates, 2012
Proteo, Inc. - Dormant Developmental Projects,2012
Proteo, Inc., Subsidiaries
Proteo, Inc., Deals Summary
Proteo Biotech Enters Into An Agreement With USAMRIID
Proteo Biotech Enters Into Co-Marketing Agreement With ARTES Biotech
Proteo Enters Into Licensing Agreement With Rhein Minapharm
Proteo Completes Private Placement Of $3.6 Million
LIST OF FIGURES
Proteo, Inc. – Pipeline by Indication, 2012
Proteo, Inc. – Pipeline by Stage of Development, 2012
Proteo, Inc. – Monotherapy Products in Pipeline, 2012
Proteo, Inc. – Pipeline By Route of Administration, 2012
Proteo, Inc. - Pipeline Products By Mechanism of Action, 2012
